State Street Exits Sangamo Therapeutics Stake
Ticker: SGMO · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, ownership-change, exit-filing
TL;DR
**State Street just dumped its Sangamo shares, watch out for price drops!**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating a change in its beneficial ownership of Sangamo Therapeutics Inc. common stock as of December 31, 2023. This filing is an 'exit filing,' meaning State Street no longer holds a reportable stake (above 5%) in Sangamo. This matters to investors because it signals a significant institutional investor has reduced or eliminated its position, which could be interpreted as a loss of confidence or a strategic portfolio adjustment.
Why It Matters
A large institutional investor like State Street reducing its stake can influence market sentiment and potentially put downward pressure on Sangamo's stock price, as it suggests a major player no longer sees the same value or growth potential.
Risk Assessment
Risk Level: medium — The exit of a major institutional investor like State Street could signal underlying concerns about Sangamo Therapeutics, potentially leading to increased stock volatility.
Analyst Insight
A smart investor would investigate the reasons behind State Street's exit from Sangamo Therapeutics Inc. and consider if this signals a broader lack of confidence in the company's future prospects before making any investment decisions.
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Sangamo Therapeutics Inc (company) — the subject company whose common stock is being reported on
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
- 04-2456637 (number) — State Street Corporation's IRS Identification Number
Forward-Looking Statements
- Sangamo Therapeutics Inc. stock price may experience downward pressure in the short term. (Sangamo Therapeutics Inc.) — medium confidence, target: 3 months
- Other institutional investors might re-evaluate their positions in Sangamo Therapeutics Inc. following State Street's exit. (institutional investors) — medium confidence, target: 6 months
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934' in the filing.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as explicitly stated under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company (issuer) of the securities being reported?
The subject company is SANGAMO THERAPEUTICS INC, as identified under 'SUBJECT COMPANY: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC' and 'SANGAMO THERAPEUTICS INC (NAME OF ISSUER)'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the common stock of Sangamo Therapeutics Inc. is 800677106, as stated under 'CUSIP NUMBER: 800677106'.
What does the 'EXIT FILING' designation mean for State Street Corporation's position in Sangamo Therapeutics Inc.?
The 'EXIT FILING' designation indicates that State Street Corporation no longer holds a reportable beneficial ownership stake (typically above 5%) in Sangamo Therapeutics Inc. common stock, meaning they have significantly reduced or sold off their position.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding SANGAMO THERAPEUTICS, INC (SGMO).